Remarkable activity of novel agents bortezomib and thalidomide in patients not responding to donor lymphocyte infusions following nonmyeloablative allogeneic stem cell transplantation in multiple myeloma

Blood. 2006 Apr 15;107(8):3415-6. doi: 10.1182/blood-2005-11-4449.
No abstract available

Publication types

  • Letter
  • Multicenter Study

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Boronic Acids / administration & dosage*
  • Bortezomib
  • Female
  • Graft vs Host Disease / etiology
  • Graft vs Host Disease / therapy
  • Humans
  • Immunosuppressive Agents / administration & dosage*
  • Lymphocyte Transfusion*
  • Male
  • Multiple Myeloma / complications
  • Multiple Myeloma / therapy*
  • Pyrazines / administration & dosage*
  • Remission Induction
  • Stem Cell Transplantation*
  • Thalidomide / administration & dosage*
  • Transplantation, Homologous

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Immunosuppressive Agents
  • Pyrazines
  • Thalidomide
  • Bortezomib